• Additionally, the primary safety measure of major adverse cardiovascular events (MACE), including death, reinfarction, stent thrombosis and stroke established the superiority of drug-eluting stents with respect to safety through one year. (dotmed.com)
  • However, excessive inhibition of neointimal formation caused delayed vascular healing with incomplete endothelialization, which has been associated with an increased risk of late stent thrombosis (ST). (acc.org)
  • Prematurely discontinuing this therapy increases the risk of stent thrombosis, which often leads to acute myocardial infarction or death. (aafp.org)
  • However, patients should restart thienopyridine therapy as soon as possible after the procedure because of the risk of late-stent thrombosis. (aafp.org)
  • The concern of stent thrombosis still an issue and dual antiplatlets therapy (DAPT) is mandatory for variable time ranging from one month to one year. (scirp.org)
  • The continuous increase in late lumen loss in conjunction with the ongoing risk of very late stent thrombosis suggests that vascular healing remains incomplete up to 5 years after implantation of first-generation drug-eluting stents. (ox.ac.uk)
  • Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. (jamanetwork.com)
  • Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial. (jamanetwork.com)
  • Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. (jamanetwork.com)
  • During extended clinical follow-up, 2 patients suffered from very late stent thrombosis showing a high degree of malapposition, protrusion, and coronary evaginations at the time of OCT investigation. (eur.nl)
  • Various anticoagulation and antiplatelet regimens are used during and after PCI to reduce the incidence of thrombosis at the site of balloon dilation and stent placement. (msdmanuals.com)
  • Delayed arterial healing, characterized by poor endothelialization, is the primary cause of late (1 month-1 year postimplantation) and very late stent thrombosis following implantation of drug-eluting stents. (nature.com)
  • The incompetent endothelium leads to late stent thrombosis and the development of in-stent neoatherosclerosis. (nature.com)
  • At a median follow-up of 3.8 years, cobalt-chromium everolimus-eluting stents (EES) were associated with lower rates of mortality, definite stent thrombosis (ST), and myocardial infarction than BMS, paclitaxel-eluting stents (PES), and sirolimus-eluting stents (SES) and less ST than BES. (ox.ac.uk)
  • Cost-effectiveness of drug-eluting stents including the economic impact of late stent thrombosis. (wustl.edu)
  • A study comparing drug-eluting stents made by Biotronik, Medtronic (NYSE:MDT) and Boston Scientific (NYSE:BSX) found no statistically significant difference on target vessel failure or stent thrombosis after three years. (drugdeliverybusiness.com)
  • Mortality, major adverse cardiovascular events (MACEs), target vessel failure, and stent thrombosis (ST) occur more frequently as the result of calcium-mediated poor lesion preparation, stent under expansion, and stent malapposition ( 2 ). (frontiersin.org)
  • A non-hierarchical analysis revealed a 0.4% cardiac death, 4.1% MI, 4.5% TVR and 2 of the total had probable stent thrombosis (ST). Given the small number of bailout 2-stent strategy arm, this study only demonstrates safety. (heart.org)
  • Drug-eluting stents (DES) were developed in the early 2000s to reduce restenosis (ie, recurrent narrowing) rates in stented coronary lesions. (medscape.com)
  • [ 2 , 3 ] There was significant improvement in angiographic results (in stent late lumen loss: 0.17 mm vs 1.00 mm) as well as clinical outcomes (binary in-lesion restenosis: 8.9% vs 36.3%) in the sirolimus stent treatment group relative to the BMS group. (medscape.com)
  • [ 4 ] Restenosis remains an issue in coronary drug-eluting stent implantation for ostial RCA lesions. (medscape.com)
  • The study, HORIZONS-AMI (Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial Infarction), showed that in heart attack patients undergoing angioplasty, the use of paclitaxel-eluting stents reduces rates of target lesion revascularization (TLR) and binary angiographic restenosis when compared to the use of bare-metal stents after one year. (dotmed.com)
  • The use of paclitaxel-eluting stents also resulted in a significant reduction in binary restenosis after 13 months, which is the rate at which the artery re-narrows at least 50 percent following implantation of the stent, and was the secondary efficacy endpoint of the trial. (dotmed.com)
  • The first-generation drug-eluting stent (DES) was associated with remarkably reduced rates of in-stent restenosis and much less need for subsequent target lesion revascularization (TLR) compared to bare-metal stents (BMS). (acc.org)
  • DES reduced the incidence of in-stent restenosis. (scirp.org)
  • 1987) Intravascular Stents to Prevent Occlusion and Restenosis after Transluminal Angioplasty. (scirp.org)
  • 1996) Patterns and Mechanisms of In-Stent Restenosis. (scirp.org)
  • Stent Anticoagulation Restenosis Study Investigators. (jamanetwork.com)
  • When used in relatively simple lesions, randomized studies have demonstrated efficacy of drug-eluting stents in significantly reducing restenosis compared with bare metal stents. (eur.nl)
  • Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial. (umassmed.edu)
  • The FDA has granted B. Braun Interventional Systems breakthrough device designation for the company's SeQuent Please ReX drug-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter for the treatment of coronary in-stent restenosis (ISR). (drugdeliverybusiness.com)
  • Drug-coated balloons (DCB), also referred to as drug-eluting balloons (DEB), were created as a way to reduce very high restenosis rates in peripheral vessels. (researchandmarkets.com)
  • They also have been investigated in clinical trials to prevent coronary artery in-stent restenosis. (researchandmarkets.com)
  • DCBs are also used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude. (researchandmarkets.com)
  • Stents reduced the restenosis rate slightly, but it was still high. (technologyreview.com)
  • Today, restenosis in coronary arteries afflicts less than 10 percent of patients thanks to the development of the drug-eluting stent (DES), which slowly releases a drug that inhibits the growth of scar tissue. (technologyreview.com)
  • The project dates to 1996, when Bill Hunter, cofounder and chief scientific officer of Angiotech Pharmaceuticals, approached J&J and other stent makers with his own solution to the restenosis problem. (technologyreview.com)
  • Using a drug was a novel approach to the problem of restenosis. (technologyreview.com)
  • Companies had tinkered with stent designs, trying to prevent restenosis, but with little success. (technologyreview.com)
  • In 23 lesions, IVL was used for the treatment of in-stent restenosis (ISR). (frontiersin.org)
  • This geographic miss is what prompted many operators to perform minimal protrusion to mitigate in-stent restenosis at that missed segment. (heart.org)
  • Initially, drug-eluting stents (DES) were compared to bare-metal stents (BMS) for efficacy. (medscape.com)
  • New York-Presbyterian Hospital and Columbia University Medical Center, together with the Cardiovascular Research Foundation (CRF), announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published in the May 7 New England Journal of Medicine. (dotmed.com)
  • Outcomes from prior registry and randomized trials of drug-eluting stents compared with bare-metal stents in heart attack patients have been conflicting. (dotmed.com)
  • These results now provide definitive evidence that paclitaxel-eluting stents are superior in efficacy to bare-metal stents and have a comparable safety profile at one year," says Dr. Stone. (dotmed.com)
  • The findings from the HORIZONS-AMI trial will have a major impact on how decisions are made regarding drug-eluting and bare-metal stents in the highest-risk patients, those in the early hours of a heart attack. (dotmed.com)
  • The HORIZONS-AMI trial, a prospective, open-label, multicenter, controlled study, enrolled 3,602 heart attack patients at 123 centers in 11 countries, 3,006 of whom were randomized to paclitaxel-eluting stents versus otherwise identical bare-metal stents. (dotmed.com)
  • Drug-eluting stents (DES) were associated with decreased rates of death, myocardial infarction (MI), and revascularization at 3 years of follow up in diabetic patients compared to bare-metal stents (BMS), according to results of a large observational study. (medicaleconomics.com)
  • Drug-eluting stents (DES) improved the principles of bare metal stents (BMS) by local drug release to inhibit neointimal growth. (scirp.org)
  • 2009) 5-Year Clinical Outcomes after Sirolimus-Eluting Stent Implantation Insights from a Patient-Level Pooled Analysis of 4 Randomized Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. (scirp.org)
  • Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents [published online ahead of print November 1, 2006]. (jamanetwork.com)
  • Bare-metal stents (BMS) are made of nickel-titanium alloy. (msdmanuals.com)
  • It is experienced in the development of medical devices and implants and provides a comprehensive portfolio of premium products in the fields of interventional cardiology and endovascular intervention including drug eluting balloons, drug eluting stents, bare metal stents, self-expandable stents, thrombus aspiration catheters and angioplasty balloon-catheters. (catalonia.com)
  • Impairment of vasorelaxation in nonstented proximal and distal segments of stented coronary arteries is more severe with drug-eluting stents than bare-metal stents, and stent-induced flow disturbances resulting in complex spatiotemporal shear stress can also contribute to increased thrombogenicity and inflammation. (nature.com)
  • The process of neoatherosclerosis occurs more rapidly, and more frequently, following deployment of drug-eluting stents than bare-metal stents. (nature.com)
  • Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. (ox.ac.uk)
  • In 1996, Johnson & Johnson was the undisputed king of bare-metal stents. (technologyreview.com)
  • Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease NATICK, Mass., and BARCELONA, Spain, May 24 /- Boston Scientific Corporation (NYSE:BSX) today announced that it has received CE Mark for its TAXUS® Liberte(TM) Long paclitaxel-eluting coronary stent system, allowing doctors to treat longer coronary artery lesions with a single. (thomasnet.com)
  • Products are designed to assist with placement and support of guidewires used in peripheral vascular procedures to deliver stents and balloons to open blockages in legs and other peripheral arteries. (thomasnet.com)
  • Thus new improvements to balloons and stents are always necessary to achieve the best results from percutaneous coronary intervention (PCI). (scirp.org)
  • An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease received treatment with paclitaxel-coated (drug-coated balloons or. (vascularnews.com)
  • Do not use paclitaxel drug-coated balloons (DCBs) or drug-eluting stents (DESs) in the routine treatment of patients with intermittent claudication until further notice, a. (vascularnews.com)
  • By Thomas Zeller The Katsanos et al meta-analysis reports an increased risk of mortality beyond one year across randomised studies of paclitaxel-coated balloons (DCB) and. (vascularnews.com)
  • interventions and outcomes with paclitaxel drug coated balloons, evolving indications for TAVI patients with severe symptomatic aortic stenosis, defining high bleeding risk in patients undergoing PCI, and percutaneous edge-to-edge repair in patients with heart failure and secondary mitral regurgitation. (emjreviews.com)
  • Drug eluting balloons are angioplasty balloons that are coated with an anti-proliferative drug, which is eluted in vessel walls during the inflation of balloon, usually at nominal pressure with a specific minimal inflation time. (researchandmarkets.com)
  • Mostly paclitaxel is used as active ingredient due to its high pharmacokinetic transfer rate into the vessel wall and it is actively used in drug eluting balloons in the U.S. market and has been already approved for use in Europe. (researchandmarkets.com)
  • The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. (researchandmarkets.com)
  • Royal Philips introduced two new balloons to its Stellarex 0.035" low-dose drug-coated balloon (DCB) portfolio. (researchandmarkets.com)
  • By fall 2018, three drug-coated balloons and two drug-eluting stents had been approved by the FDA for use in the femoral-popliteal circulation for PAD. (sirweb.org)
  • These stents are FDA approved for single de novo coronary lesions of limited length within specific diameter size ranges. (medscape.com)
  • [ 1 ] which compared the sirolimus-eluting CYPHER stent with its noncoated counterpart, the BX velocity stent, in 238 patients with de novo lesions less than 18 mm in length in native coronary arteries 2.5-3.5 mm in diameter. (medscape.com)
  • The SIRIUS trial, which included 1058 patients with workhorse lesions who were randomly assigned to either sirolimus-eluting stents or BMS, demonstrated the long-term efficacy and safety of sirolimus-eluting stents. (medscape.com)
  • In a 5-year study of outcomes from the j-CYPHER registry which compared sirolimus-eluting stent treatment in 397 patients with ostial right coronary artery (RCA) lesions with 3716 patients with nonostial RCA lesions, researchers concluded that sirolimus-eluting stent implantation for ostial RCA was associated with a higher risk of target legion revascularization than when used in patients with nonostial RCA lesions. (medscape.com)
  • The advanced low-profile delivery system facilitates precise delivery of the stent across challenging lesions. (prnewswire.com)
  • Exceptional stent deliverability offers cardiologists the potential to treat patients with difficult-to-reach lesions. (prnewswire.com)
  • The ION Stent has been evaluated in the PERSEUS trial, which reported 12-month results in March 2010 , demonstrating positive safety and efficacy outcomes in workhorse lesions compared to the TAXUS® Express2® Stent System. (prnewswire.com)
  • Stents are used frequently for acute myocardial infarction, ostial or left main disease, chronic total occlusions, and bifurcation lesions. (msdmanuals.com)
  • It really was the place to be to learn about the hottest news in cardiovascular interventions and cutting-edge techniques, with topics including acute heart failure, bifurcation lesions, carotid stenting, mitral valve replacement and repair, ST-elevation myocardial infarction (STEMI), stents and scaffolds, and transcatheter aortic valve implantation (TAVI), to name a few. (emjreviews.com)
  • The study pitted the In.Pact AV DCB against PTA in patients with de novo or non-stented restenotic arteriovenous fistulae lesions. (drugdeliverybusiness.com)
  • The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. (researchandmarkets.com)
  • The new 200mm and 150mm Stellarex 0.035" low-dose DCBs have received approval from the U.S. Food and Drug Administration (FDA) for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries, both arteries in the upper leg. (researchandmarkets.com)
  • A total of 87 de novo lesions were treated by IVL with the following indications: 25 before attempting other balloon-based devices (primary IVL), 51 after the failure of non-compliant balloon dilatation (secondary IVL), and 11 after stent implantation because of stent under expansion (bailout IVL). (frontiersin.org)
  • Sirolimus, paclitaxel, or zotarolimus DES were deployed in 73 patients (67% with Medina 1,1,1 lesions and 44% of unprotected distal left main disease) using the TAP technique. (heart.org)
  • Incidence of thrombotic stent occlusion during the first three months after sirolimus-eluting stent implantation in 500 consecutive patients. (jamanetwork.com)
  • The investigators noted that 1 year of clinical follow-up may not be sufficient to assess late outcomes (very late ST). Also, because very high-risk patients were not included, the results cannot be generalized to the entire population of patients undergoing stenting. (acc.org)
  • Also, the benefit of rivaroxaban plus aspirin over aspirin alone in terms of cardiovascular and ischemic limb outcomes was consistent regardless of whether patients got a drug-coated device or not. (medscape.com)
  • Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. (ox.ac.uk)
  • We investigated clinical and angiographic outcomes of sirolimus-eluting (SES) and paclitaxel-eluting stents (PES) at 5 years as part of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization (SIRTAX) LATE study. (ox.ac.uk)
  • CONCLUSIONS: Long-term follow-up of first-generation drug-eluting stents shows no significant differences in clinical and angiographic outcomes between SES and PES. (ox.ac.uk)
  • Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. (jamanetwork.com)
  • Current ACC/American Heart Association/Society for Cardiovascular Angiography and Interventions recommendations suggest, at a minimum, patients should be treated with clopidogrel 75 mg and aspirin 325 mg for 1 month after BMS implantation, 3 months after sirolimus-eluting stent (SES) implantation, 6 months after paclitaxel DES implantation, and, ideally, up to 12 months for patients not at high risk for bleeding. (acc.org)
  • and six months after paclitaxel drug-eluting stent implantation (ideally, up to 12 months if they are not at high risk for bleeding). (aafp.org)
  • The ION Stent is backed by the proven safety and efficacy of the TAXUS clinical program, which spans 10 years of research in nearly 50,000 patients in 28 pre- and post-market studies. (prnewswire.com)
  • The PERSEUS data confirmed that the proven TAXUS drug and polymer combination has been successfully transferred to the advanced ION Stent platform with excellent performance and comparable safety and efficacy. (prnewswire.com)
  • OBJECTIVES: This study sought to investigate the long-term safety and efficacy of durable polymer-based DES, bioabsorbable polymer-based biolimus-eluting stents (BES), and BMS by means of network meta-analysis. (ox.ac.uk)
  • No hint of increased mortality risk in association with the use of paclitaxel-coated devices for treatment of peripheral artery disease was detected in VOYAGER PAD, a multithousand-patient randomized trial with long-term follow-up and ascertainment of vital status in 99.6% of participants. (medscape.com)
  • Observers opined that the VOYAGER PAD findings effectively put to rest a nearly 2-year-old controversy over whether paclitaxel-coated devices for treatment of peripheral artery disease (PAD) carry an increased mortality risk. (medscape.com)
  • Based on the application, the solutions in the drug-eluting stents market can be bifurcated into peripheral vascular diseases, as well as coronary diseases. (tmrresearchblog.com)
  • The most prominent drug-eluting stents market share was held in the recent past by peripheral vascular diseases. (tmrresearchblog.com)
  • Rising demand for these solutions, on the advent of the increasing instances of complicated peripheral vascular disorder cases is the strongest motivator for the growth of this segment in the drug-eluting stents market. (tmrresearchblog.com)
  • Treatment of peripheral arteries with stents can be a challenging procedure, particularly in the superficial femoral artery. (ahima.org)
  • Physicians may identify the stent used as the Zilver PTX paclitaxel drug-eluting peripheral stent from Cook Medical. (ahima.org)
  • The stent is intended to treat symptomatic peripheral arterial disease in the above-the-knee vessel. (ahima.org)
  • The title for code 00.55 was revised to "insertion of drug-eluting stent(s) of other peripheral vessel(s)," and an excludes note was added to the tabular list to exclude the insertion of drug-eluting stent(s) of superficial femoral artery (00.60). (ahima.org)
  • Becton Dickinson (NYSE:BDX) is planning to close a Minnesota plant that makes its Lutonix drug-coated balloon next year, as the company looks to consolidate its peripheral intervention business. (drugdeliverybusiness.com)
  • The FDA said last week that its preliminary review of long-term follow-up data found a "potentially concerning signal" of increased long-term mortality in people with peripheral artery disease who were treated with paclitaxel-coated devices compared to those treated with bare devices. (drugdeliverybusiness.com)
  • Stents revolutionized the treatment of atherosclerosis in coronary and peripheral arteries, but they did little to address one of the chief problems with balloon angioplasty. (technologyreview.com)
  • Paclitaxel drug-eluting stents for coronary artery placement are sold under the trade name Taxus by Boston Scientific in the United States. (wikipedia.org)
  • Paclitaxel drug-eluting stents for femoropopliteal artery placement are also available. (wikipedia.org)
  • Airway bypass was performed with a fiberoptic bronchoscope in three steps: identification of a blood vessel-free location with a Doppler probe at the level of segmental bronchi, fenestration of the bronchial wall, and placement of a paclitaxel-eluting stent to expand and maintain the new passage between the airway and adjacent lung tissue. (nih.gov)
  • In combination with aspirin, thienopyridine therapy (primarily clopidogrel [Plavix] in the United States) may reduce the incidence of early major adverse cardiac events in patients who have undergone placement of a bare-metal stent compared with aspirin therapy alone or in combination with warfarin (Coumadin). (aafp.org)
  • 1994) A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease. (scirp.org)
  • Facilitated PCI is defined as the intent to perform a PCI (either conventional balloon angioplasty or coronary stent placement) in the setting of STEMI following treatment with either a full dose or half dose of a fibrinolytic agent. (wikidoc.org)
  • Drug-eluting stents (DES) are balloon-mounted, expandable, slotted tubular or multilink scaffolds constructed of a stainless steel or cobalt chromium matrix. (medscape.com)
  • In April 2011 , results from an analysis of pooled patient-level data from 2,298 patients enrolled in the PERSEUS and TAXUS ATLAS clinical trials showed that the ION Stent demonstrated significantly lower rates of major adverse cardiac events, target lesion failure and myocardial infarction compared to the TAXUS® Liberte® Paclitaxel-Eluting Stent System. (prnewswire.com)
  • Boston Scientific Corp. 's Taxus Liberte drug-eluting stent was given regulatory approvals in Japan, clearing the way for its appearance on the Japanese market. (massdevice.com)
  • The paclitaxel-eluting stent had a rate of 10.0 percent and the bare-metal stent had a rate of 22.9 percent. (dotmed.com)
  • Nor did all-cause mortality differ by device type, be it paclitaxel-coated balloon versus plain balloon angioplasty, or drug-eluting stent versus bare-metal stent. (medscape.com)
  • Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. (jamanetwork.com)
  • There is a so called 'bare metal stent' which is usually made out of stainless steel and the second type is a 'drug eluting stent' which is the bare metal stent but this time covered with a drug called Rapamycin or Paclitaxel. (heart-specialist.org)
  • Zotarolimus-eluting stents (ZES) have been associated with a higher rate of neointimal coverage at 8 months than SES on intravascular ultrasound (IVUS) and had a pattern of neointimal coverage similar to that of BMS on angioscopy. (acc.org)
  • Phosphorylcholine-based zotarolimus-eluting stents had lower rates of definite ST than SES and lower rates of myocardial infarction than BMS and PES. (ox.ac.uk)
  • The 3,514-patient Bio-Resort trial compared Biotronik's Orsiro biodegradable sirolimus-eluting stent, Medtronic's thin-strut zotarolimus-eluting Resolute Integrity stent and the Synergy biodegradable everolimus-eluting stent. (drugdeliverybusiness.com)
  • In September 2001, NICE recommended paclitaxel for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. (wikipedia.org)
  • The imbroglio, which was ignited by a meta-analysis of clinical trials with substantial amounts of missing follow-up data, triggered an Food and Drug Administration warning letter to health care providers which threw the field of vascular medicine into disarray. (medscape.com)
  • Some of the key strategies employed by these leading players in the drug-eluting stents market for capturing a larger share of the industry include regional expansion, increasing the number of ongoing clinical trials for innovative drug development and discovery processes, and product innovations through extensive research and development. (tmrresearchblog.com)
  • The two companies signed a pact in 1997 that led to the development of Boston Scientific's Taxus stent, which was introduced in the U.S. in March 2004. (technologyreview.com)
  • Coronary stents are generally indicated to increase coronary vessel diameter in the setting of ischemia due to coronary blockage, either by a combination of acute recoil, arterial contraction of a previously treated segment, and/or local neointimal hyperplasia. (medscape.com)
  • Boston Scientific only company to offer two distinct drug-eluting stent platforms NATICK, Mass., Jan. 11 // -- Boston Scientific Corporation (NYSE:BSX) today announced the international launch and first implantation of the PROMUS(TM) Everolimus-Eluting Stent, making Boston Scientific the only company to offer two distinct drug-eluting stent (DES) platforms. (thomasnet.com)
  • In October 2009 , the Company received CE Mark approval for the PROMUS Element™ Everolimus-Eluting Stent System. (prnewswire.com)
  • Biodegradable polymer sirolimus -eluting stents versus durable polymer everolimus -eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. (msdmanuals.com)
  • Outside the U.S., including CE Mark countries where it was approved in May 2010 , the ION Stent System is commercialized as the TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System. (prnewswire.com)
  • A drug-eluting stent ( Taxus Express2 Atom Paclitaxel-Eluting Coronary Stent System , Boston Scientific) was approved for use in small coronary vessels for the treatment of coronary artery disease. (formularywatch.com)
  • Cook has extended its Zilver PTX product portfolio with a 140mm drug-eluting stent. (vascularnews.com)
  • A note follows code 00.60 in the tabular list to code also any angioplasty or atherectomy of other noncoronary vessels (39.50), the number of vascular stents inserted (00.45-00.48), the number of vessels treated (00.40-00.43), and the procedure on vessel bifurcation (00.44). (ahima.org)
  • The active substance coated on the drug eluting balloon should be lipophilic in nature to have a high absorption rate through the vessel wall. (researchandmarkets.com)
  • The balloon is then inflated to press the stent against the vessel wall. (heart-specialist.org)
  • This study removes much of the uncertainty and concern about the efficacy and safety of drug-eluting stents in this clinical setting. (dotmed.com)
  • To assess the safety and early clinical results of a multicenter evaluation of airway bypass with paclitaxel-eluting stents for selected patients with severe emphysema. (nih.gov)
  • Thirty-five patients received the airway bypass procedure with a median of 8 stents implanted per patient. (nih.gov)
  • Of the 4,316 patients included in the prespecified analysis by Hess, a cardiologist at the University of Colorado at Denver, Aurora, 31% received a paclitaxel-coated device. (medscape.com)
  • At 3.5 years of follow-up, they had a 10.2% all-cause mortality rate, significantly less than the 13.5% rate in patients who didn't get a drug-coated device. (medscape.com)
  • Personally, I think this is probably the most impactful data seen regarding the paclitaxel issue in almost 2 years because it is randomized data, it's prospectively collected data, and - most importantly from my perspective - they were able to collect vital statistics on more than 99.5% of the patients," he added. (medscape.com)
  • Researchers then identified 5,423 evaluable diabetic patients and excluded 372 who had received both stent types. (medicaleconomics.com)
  • Among DES patients, 75 percent received sirolimus stents and 25 percent received paclitaxel versions. (medicaleconomics.com)
  • The AHA, ACC, the Society for Cardiovascular Angiography and Interventions, the American College of Physicians, the American College of Surgeons, and the American Dental Association have released a science advisory on the importance of antiplatelet therapy in patients with coronary artery stents. (aafp.org)
  • To help eliminate premature cessation of therapy, physicians should discuss the need for dual antiplatelet therapy with their patients before implanting a stent. (aafp.org)
  • Physicians should also strongly consider whether to avoid a drug-eluting stent in patients who are not expected to comply with 12 months of thienopyridine therapy. (aafp.org)
  • For patients treated with a drug-eluting stent who are undergoing procedures for which thienopyridine therapy must be discontinued, aspirin therapy should be continued if possible. (aafp.org)
  • I look forward to using the ION Stent in my daily practice, and I believe our patients will benefit from its improved acute performance," said Louis Cannon , M.D., FACC, FACA, Heart and Vascular Institute Program Director at Northern Michigan Regional Hospital in Petoskey, MI. (prnewswire.com)
  • The ION Stent offers physicians and their patients the broadest size matrix on the market, and includes both monorail® and over-the-wire versions, with sizes ranging in diameter from 2.25 mm to 4.00 mm and lengths of 8 mm to 38 mm. (prnewswire.com)
  • The PERSEUS clinical program compared the ION Stent to prior-generation Boston Scientific stents in more than 1,600 patients in two parallel trials at 90 centers worldwide. (prnewswire.com)
  • They recruited 212 patients with intermittent claudication who had never had invasive treatment-which immediately made me realise the study couldn't have been done in America, where at the first twinge of calf pain you get a stent or balloon stuck down your femoral artery. (bmj.com)
  • 2009) EUROASPIRE III: A Survey on the Lifestyle, Risk Factors and Use of Cardioprotective Drug Therapies in Coronary Patients from Twenty-Two European Countries. (scirp.org)
  • 1994) A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease. (scirp.org)
  • Methods: A total of 88 event-free patients with 1 randomly selected lesion were suitable for final OCT analysis 5 years after drug-eluting stent implantation. (eur.nl)
  • Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. (wustl.edu)
  • A study comparing the Resolute Onyx drug-eluting stent from Medtronic (NYSE:MDT) and the BioFreedom stent made by Biosensors International (PINK:BSNRY) showed the Medtronic device to be non-inferior in patients on a one-month dual anti-platelet therapy regimen, according to results presented yesterday at the annual Transcatheter Cardiovascular Technologies conference in San Francisco. (drugdeliverybusiness.com)
  • The necessity usually for you to have another angioplasty to the same artery at the same place after a drug eluting stent is less than 3 or 4 in every hundred patients. (heart-specialist.org)
  • 1 It was evaluated in vitro and in two independent series of patients undergoing elective drug-eluting stent (DES) implantation on a bifurcation lesion. (heart.org)
  • In 2009 Al-Rashdan et al published their series of 156 consecutive patients who underwent TAP stenting. (heart.org)
  • Factors that may contribute to premature cessation of thienopyridine therapy include drug costs, instructions from a physician or dentist to discontinue therapy before a procedure, and inadequate patient education about the importance of continuing therapy. (aafp.org)
  • Although as a community we've continued to struggle with this issue of paclitaxel and mortality, VOYAGER PAD does fill many of the gaps and addresses many of the limitations of currently available data," Connie N. Hess, MD , said in reporting results of a prespecified analysis of the trial at the Transcatheter Cardiovascular Research Therapeutics virtual annual meeting. (medscape.com)
  • In the weighted analysis, the all-cause mortality rate at 3.5 years was 12.1% in paclitaxel-coated device recipients and 12.6% in those who didn't get such devices. (medscape.com)
  • The ION Stent System incorporates a unique platinum chromium (PtCr) alloy designed specifically for coronary stenting and intended to improve the acute performance of coronary stent implantation in the treatment of coronary artery disease. (prnewswire.com)
  • In a pre-stent era, balloon angioplasty was the mainstay of coronary revascularization in which an inflatable balloon-tipped catheter was inserted percutaneously through an arterial entry site in the extremity and advanced into the coronary arteries. (statpearls.com)
  • Because one of the strongest predictors for ST is early discontinuation of clopidogrel, prolonged dual antiplatelet therapy (DAPT) is highly recommended post-stenting. (acc.org)
  • The growth within the drug-eluting stents market is driven by several key factors, such as the rising burden of the cardiovascular diseases, as well as the advent of completely bioresorbable stent products. (tmrresearchblog.com)
  • The Company anticipates FDA approval for the PROMUS Element Stent System in mid 2012. (prnewswire.com)
  • Drug-eluting stents (DES) are a standard metallic coronary stent with a polymer coating and an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation. (medscape.com)
  • Attached to the stent is a polymer that is embedded with an antiproliferative drug, which allows drug elution into the coronary wall for weeks to months after stent implantation to reduce the local proliferative healing response. (medscape.com)
  • While DEB has only antiproliferative drug coating without an underlying metallic structure of the stent, BRS is also devoid of metallic structure and is entirely resorbed in a few months after serving their purpose. (statpearls.com)
  • the authors are both in close relation with CYPHER and PACLITAXEL intra coronary devices manufactors! (jwatch.org)